Key facts
- This page summarizes Kenneth Pienta's Form 4 filing for Cue Biopharma, Inc. (CUE).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 29 Mar 2022, 16:12.
Kenneth Pienta - 25 Mar 2022 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- CUE
- Reported as of
- 25 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 29 Mar 2022, 16:12:35 UTC
- Prior SEC filing
- 21 Dec 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kenneth Pienta by Colin Sandercock, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Kenneth Pienta filed Form 4 for Cue Biopharma, Inc. (CUE) on 29 Mar 2022.
Change
- Previous filing in this sequence was filed on 21 Dec 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CUE
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +40,000
- Change %
- Price
- $0.000000
- Shares after
- 40,000
- Date
- 25 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,000
- Exercise price
- $5.01
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
1. This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 25, 2022.